Clinical Study
Steroid-Refractory Acute GVHD: Predictors and Outcomes
Table 6
The Effect of severity, hyperacute GVHD, and response to corticosteroids on nonrelapse morality.
| Hyperacute | NRM at 100 days | NRM at 1 year | Group | Grade | GVHD | CR or PR | | % CI | HR | | % CI | HR | |
| 1 | 1 or 2 | No | Yes | 110 | 9% | Reference | — | 27% | Reference | — | 2 | 1 or 2 | No | No | 60 | 23% | 2.8 | 0.01 | 55% | 2.5 | <0.001 | 3 | 1 or 2 | Yes | Yes | 29 | 3% | 0.4 | 0.3 | 34% | 1.1 | 0.7 | 4 | 1 or 2 | Yes | No | 31 | 31% | 4.9 | <0.001 | 45% | 2.5 | 0.003 | 5 | 3 or 4 | No | Yes | 20 | 25% | 2.9 | 0.05 | 35% | 1.4 | 0.4 | 6 | 3 or 4 | No | No | 24 | 50% | 7.6 | <0.001 | 75% | 4.7 | <0.001 | 7 | 3 or 4 | Yes | Yes | 2 | 100% | Excluded | — | 100% | Excluded | — | 8 | 3 or 4 | Yes | No | 11 | 70% | 11.6 | <0.001 | 80% | 6.2 | <0.001 |
|
|
% CI: percent cumulative incidence; NRM: nonrelapse mortality; —: nonapplicable, KM: Kaplan-Meier.
|